FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Raymond Alexanian

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance

Co-author Network

Publications

TOP 3
Raymond Alexanian; Kay Delasalle; Michael Wang
High frequencies of response after limited primary therapy for multiple myeloma.
Raymond Alexanian; Kay Delasalle; Sheeba Thomas; Michael Wang; Donna Weber
Curability of multiple myeloma.
Valerie Reed; Jatin Shah; Ferial Shihadeh; Sheeba K Thomas; Donna M Weber; Chul Ha; Ali Mazloom; L Jeffery Medeiros; Robert Z Orlowski; Raymond Alexanian; Isidora Y Arzu; Bouthaina S Dabaja
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Raymond Alexanian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Raymond Alexanian; Kay Delasalle; Michael Wang
High frequencies of response after limited primary therapy for multiple myeloma.
Clinical lymphoma, myeloma & leukemia 2013;13(2):119-22.
2012: Raymond Alexanian; Kay Delasalle; Sheeba Thomas; Michael Wang; Donna Weber
Curability of multiple myeloma.
Bone marrow research 2012;2012():916479.
2011: Valerie Reed; Jatin Shah; Ferial Shihadeh; Sheeba K Thomas; Donna M Weber; Chul Ha; Ali Mazloom; L Jeffery Medeiros; Robert Z Orlowski; Raymond Alexanian; Isidora Y Arzu; Bouthaina S Dabaja
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
Cancer 2011;117(19):4468-74.
2010: Michael Wang; Kay Delasalle; Sergio Giralt; Raymond Alexanian
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Hematology (Amsterdam, Netherlands) 2010;15(2):70-3.
2010: M Wang; K Delasalle; L Feng; S Thomas; Sergio Giralt; M Qazilbash; B Handy; J J Lee; Raymond Alexanian
CR represents an early index of potential long survival in multiple myeloma.
Bone marrow transplantation 2010;45(3):498-504.
2008: Sundar Jagannath; Bart Barlogie; James R Berenson; David S Siegel; David Irwin; Paul G Richardson; Ruben Niesvizky; Raymond Alexanian; Steven A Limentani; Melissa Alsina; Dixie Esseltine; Kenneth C Anderson
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
2007: Michael Wang; Sergio Giralt; Kay Delasalle; Beverly C Handy; Raymond Alexanian
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Hematology (Amsterdam, Netherlands) 2007;12(3):235-9.
2007: Anna Christoforidou; Rima M Saliba; Patricia Williams; Muzaffar H Qazilbash; Linda Roden; Ana Aleman; Donna Weber; Floralyn Mendoza; Donald A Podoloff; Richard Wendt; Hazel Breitz; Raymond Alexanian; Richard Champlin; Sergio Giralt
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(5):543-9.
2007: Sheeba Thomas; Raymond Alexanian
Current treatment strategies for multiple myeloma.
Clinical lymphoma & myeloma 2007;7 Suppl 4():S139-44.
2006: Paul G Richardson; Hannah R Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; shashank singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven A Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
2005: James R Berenson; Sundar Jagannath; Bart Barlogie; David T Siegel; Raymond Alexanian; Paul G Richardson; David Irwin; Melissa Alsina; S Vincent Rajkumar; Gordan Srkalovic; shashank singhal; Steven A Limentani; Ruben Niesvizky; Dixie Esseltine; Elizabeth Trehu; David P Schenkein; Kenneth C Anderson
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
2005: Lia A Moulopoulos; Dimitra Gika; Athanasios Anagnostopoulos; Kay Delasalle; Donna Weber; Raymond Alexanian; Meletios A Dimopoulos
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1824-8.
2005: M Amit-Vazina; Shishir Shishodia; David Harris; Quin Van; Michael Wang; Donna Weber; Raymond Alexanian; Moshe Talpaz; Bharat B Aggarwal; Zeev Estrov
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.
British journal of cancer 2005;93(1):70-80.
2005: Michael Wang; Donna M Weber; Kay Delasalle; Raymond Alexanian
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
American journal of hematology 2005;79(3):194-7.
2005: Sundar Jagannath; Bart Barlogie; James R Berenson; shashank singhal; Raymond Alexanian; Gordan Srkalovic; Robert Z Orlowski; Paul G Richardson; Jessica Anderson; Darrell Nix; Dixie Esseltine; Kenneth C Anderson
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
2005: Meletios A Dimopoulos; Giampaolo Merlini; Veronique Leblond; Athanasios Anagnostopoulos; Raymond Alexanian
How we treat Waldenström's macroglobulinemia.
Haematologica 2005;90(1):117-25.
2004: Sundar Jagannath; Bart Barlogie; James Berenson; David Siegel; David Irwin; Paul G Richardson; Ruben Niesvizky; Raymond Alexanian; Steven A Limentani; Melissa Alsina; Julian Adams; M Kauffman; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
2004: Meletios A Dimopoulos; Raymond Alexanian; Dimitra Gika; Athanasios Anagnostopoulos; Constantinos Zervas; Athanasios Zomas; Marie-Christine Kyrtsonis; Nikolaos Anagnostopoulos; Gerassimos A Pangalis; Donna M Weber
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
Leukemia & lymphoma 2004;45(10):2057-61.
2004: Raymond Alexanian; Donna Weber; Kay Delasalle; Beverly C Handy; Richard Champlin; Sergio Giralt
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.
Bone marrow transplantation 2004;34(3):229-34.
2004: Athanasios Anagnostopoulos; Ana Aleman; Gregory D Ayers; Michele Donato; Richard Champlin; Donna Weber; Raymond Alexanian; Sergio Giralt
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Cancer 2004;100(12):2607-12.
2004: Alok C Bharti; Shishir Shishodia; James M Reuben; Donna Weber; Raymond Alexanian; Saroj Raj-Vadhan; Zeev Estrov; Moshe Talpaz; Bharat B Aggarwal
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
Blood 2004;103(8):3175-84.
2004: Michele L Donato; Ana Aleman; Richard E Champlin; Donna Weber; Raymond Alexanian; Cindy Ippoliti; Marcos De Lima; Athanasios Anagnostopoulos; Sergio Giralt
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
Leukemia & lymphoma 2004;45(4):755-9.
2004: Athanasios Anagnostopoulos; Ana Aleman; Y Yang; Michele Donato; Donna Weber; Richard Champlin; T Smith; Raymond Alexanian; Sergio Giralt
Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy.
Bone marrow transplantation 2004;33(6):623-8.
2003: Raymond Alexanian; Donna Weber; Athanasios Anagnostopoulos; Kay Delasalle; Michael Wang; Kim Rankin
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Seminars in hematology 2003;40(4 Suppl 4):3-7.
2003: Sergio Giralt; William I Bensinger; Mark Goodman; Donald A Podoloff; Janet F Eary; Richard Wendt; Raymond Alexanian; Donna Weber; David Maloney; Leona A Holmberg; Joseph Rajandran; Hazel Breitz; Richard Ghalie; Richard Champlin
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
Blood 2003;102(7):2684-91.
2003: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Athanasios Anagnostopoulos; Donna Weber; Kim Rankin; Kay Delasalle; Raymond Alexanian
Thalidomide and dexamethasone for resistant multiple myeloma.
British journal of haematology 2003;121(5):768-71.
2003: Donna M Weber; Meletios A Dimopoulos; Kay Delasalle; Kim Rankin; Maria Gavino; Raymond Alexanian
2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):243-7.
2003: Raymond Alexanian; Donna Weber; Kay Delasalle; Fernando Cabanillas; Meletios A Dimopoulos
Asymptomatic Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):206-10.
2003: Robert A Kyle; Steve P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav V Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Seminars in oncology 2003;30(2):116-20.
2003: Donna Weber; Kim Rankin; Maria Gavino; Kay Delasalle; Raymond Alexanian
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):16-9.
2002: Sergio Giralt; Ana Aleman; Athanasios Anagnostopoulos; Donna Weber; Issa Khouri; Paolo Anderlini; Jeffrey J Molldrem; Naoto T Ueno; Michele Donato; Martin Korbling; James L Gajewski; Raymond Alexanian; Richard Champlin
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Bone marrow transplantation 2002;30(6):367-73.
2002: Raymond Alexanian; Donna Weber; Sergio Giralt; Kay Delasalle
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1116-9.
2002: Richard B Wilder; Chul Ha; James D Cox; Donna Weber; Kay Delasalle; Raymond Alexanian
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
Cancer 2002;94(5):1532-7.
2001: Raymond Alexanian; Donna Weber
Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(9-10):550-2.
2001: Adnan Mansoor; L Jeffrey Medeiros; Donna M Weber; Raymond Alexanian; Kimberly Hayes; Dan Jones; Raymond Lai; Armand B. Glassman; Carlos E Bueso-Ramos
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course.
American journal of clinical pathology 2001;116(4):543-9.
2001: Raymond Alexanian; Donna Weber; Sergio Giralt; Meletios A Dimopoulos; Kay Delasalle; T Smith; Richard Champlin
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.
Bone marrow transplantation 2001;27(10):1037-43.
2001: Athanasios Anagnostopoulos; Meletios A Dimopoulos; Ana Aleman; Donna Weber; Raymond Alexanian; Richard Champlin; Sergio Giralt
High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia.
Bone marrow transplantation 2001;27(10):1027-9.
2001: Avichai Shimoni; Terry L Smith; Ana Aleman; Donna Weber; Meletios A Dimopoulos; Paolo Anderlini; Borje Andersson; David F Claxton; Naoto T Ueno; Issa Khouri; Michele Donato; Martin Korbling; Raymond Alexanian; Richard Champlin; Sergio Giralt
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Bone marrow transplantation 2001;27(8):821-8.
2000: Raymond Alexanian; Donna Weber; Meletios A Dimopoulos; Kay Delasalle; T L Smith
Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.
American journal of hematology 2000;65(3):204-9.
2000: Meletios A Dimopoulos; Lia A Moulopoulos; Alice Maniatis; Raymond Alexanian
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Blood 2000;96(6):2037-44.
2000: Meletios A Dimopoulos; Lia A Moulopoulos; I Datseris; Donna Weber; Kay Delasalle; Dimitra Gika; Raymond Alexanian
Imaging of myeloma bone disease--implications for staging, prognosis and follow-up.
Acta oncologica (Stockholm, Sweden) 2000;39(7):823-7.
1999: Robert H Liebross; Chul Ha; James D Cox; Donna Weber; Kay Delasalle; Raymond Alexanian
Clinical course of solitary extramedullary plasmacytoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;52(3):245-9.
1999: Raymond Alexanian; Donna Weber; F Liu
Differential diagnosis of monoclonal gammopathies.
Archives of pathology & laboratory medicine 1999;123(2):108-13.
1998: Robert H Liebross; Chul Ha; James D Cox; Donna Weber; Kay Delasalle; Raymond Alexanian
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.
International journal of radiation oncology, biology, physics 1998;41(5):1063-7.
1998: Chu-Myong Seong; Kay Delasalle; Kimberly Hayes; Donna Weber; Meletios A Dimopoulos; J Swantkowski; Yang Huh; Armand B. Glassman; Richard Champlin; Raymond Alexanian
Prognostic value of cytogenetics in multiple myeloma.
British journal of haematology 1998;101(1):189-94.
1997: Donna M Weber; Meletios A Dimopoulos; L A Moulopoulos; Kay Delasalle; T Smith; Raymond Alexanian
Prognostic features of asymptomatic multiple myeloma.
British journal of haematology 1997;97(4):810-4.
1997: Sergio Giralt; Donna Weber; MI Colome; Meletios A Dimopoulos; RC Mehra; Koen van Besien; James L Gajewski; Borje Andersson; Issa Khouri; Donna Przepiorka; B von Wolff; Kay Delasalle; Martin Korbling; D Seong; Raymond Alexanian; Richard Champlin
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):667-73.
1996: Meletios A Dimopoulos; Donna Weber; H Kantarjian; Kay Delasalle; Raymond Alexanian
HyperCVAD for VAD-resistant multiple myeloma.
American journal of hematology 1996;52(2):77-81.
1995: Danai D Daliani; Donna Weber; Raymond Alexanian
Light-heavy chain deposition disease progressing to multiple myeloma.
American journal of hematology 1995;50(4):296-8.
1995: D Weber; Meletios A Dimopoulos; Frank A Sinicrope; Raymond Alexanian
VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Leukemia & lymphoma 1995;19(1-2):159-63.
1995: Raymond Alexanian; Meletios A Dimopoulos; Kay Delasalle; Jeane Hester; Richard Champlin
Myeloablative therapy for primary resistant multiple myeloma.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():118-21.
1995: Lia A Moulopoulos; Meletios A Dimopoulos; Terry L Smith; Donna M Weber; Kay Delasalle; HI Libshitz; Raymond Alexanian
Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):251-6.
1995: Meletios A Dimopoulos; Donna Weber; Kay Delasalle; Michael Keating; Raymond Alexanian
Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(1):49-52.
1994: Raymond Alexanian; Meletios A Dimopoulos; Jeane Hester; Kay Delasalle; Richard Champlin
Early myeloablative therapy for multiple myeloma.
Blood 1994;84(12):4278-82.
1994: Meletios A Dimopoulos; Andrew Lamb; Donna Weber; Susan O'Brien; Elihu Estey; Kay Delasalle; E Rose; Fernando Cabanillas; Michael Keating; Raymond Alexanian
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2694-8.
1994: Meletios A Dimopoulos; Antonio Palumbo; Kay Delasalle; Raymond Alexanian
Primary plasma cell leukaemia.
British journal of haematology 1994;88(4):754-9.
1994: Meletios A Dimopoulos; S Arbuck; M Huber; Donna Weber; R Luckett; Kay Delasalle; Raymond Alexanian
Primary therapy of multiple myeloma with paclitaxel (taxol).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(8):757-9.
1994: Meletios A Dimopoulos; Jeane Hester; Y Huh; Richard Champlin; Raymond Alexanian
Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.
British journal of haematology 1994;87(4):730-4.
1994: David H Vesole; Bart Barlogie; Sundar Jagannath; B Cheson; Guido Tricot; Raymond Alexanian; John Crowley
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
Blood 1994;84(3):950-6.
1994: Meletios A Dimopoulos; Donna M Weber; Jeane Hester; Kay Delasalle; Richard Champlin; Raymond Alexanian
Intensive sequential therapy for VAD-resistant multiple myeloma.
Leukemia & lymphoma 1994;13(5-6):479-84.
1994: Meletios A Dimopoulos; Raymond Alexanian
Waldenstrom's macroglobulinemia.
Blood 1994;83(6):1452-9.
1994: Meletios A Dimopoulos; Donna M Weber; Andrew Lamb; Michael Keating; Raymond Alexanian
2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):288-9.
1994: Raymond Alexanian; Meletios A Dimopoulos
The treatment of multiple myeloma.
The New England journal of medicine 1994;330(7):484-9.
1994: Raymond Alexanian; Meletios A Dimopoulos; T Smith; Kay Delasalle; Bart Barlogie; Richard Champlin
Limited value of myeloablative therapy for late multiple myeloma.
Blood 1994;83(2):512-6.
1993: Meletios A Dimopoulos; Donna Weber; Kay Delasalle; Raymond Alexanian
Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Cancer 1993;72(9):2589-92.
1993: Meletios A Dimopoulos; Raymond Alexanian; Donna Przepiorka; Jeane Hester; Borje Andersson; Sergio Giralt; RC Mehra; Koen van Besien; Kay Delasalle; C Reading
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
Blood 1993;82(8):2324-8.
1993: Lia A Moulopoulos; Meletios A Dimopoulos; Donna Weber; L Fuller; HI Libshitz; Raymond Alexanian
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(7):1311-5.
1993: Meletios A Dimopoulos; Kay Delasalle; Richard Champlin; Raymond Alexanian
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.
British journal of haematology 1993;83(2):240-4.
1993: Meletios A Dimopoulos; Andrew Lamb; Elihu Estey; Susan O'Brien; Kay Delasalle; Michael J Keating; Emil J Freireich; Raymond Alexanian
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Meletios A Dimopoulos; A Moulopoulos; T Smith; Kay Delasalle; Raymond Alexanian
Risk of disease progression in asymptomatic multiple myeloma.
The American journal of medicine 1993;94(1):57-61.
1993: Meletios A Dimopoulos; Susan O'Brien; Andrew Lamb; E E Estey; Michael J Keating; Raymond Alexanian
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Leukemia & lymphoma 1993;11 Suppl 2():105-8.
1992: Raymond Alexanian; Meletios A Dimopoulos; Kay Delasalle; Bart Barlogie
Primary dexamethasone treatment of multiple myeloma.
Blood 1992;80(4):887-90.
1992: Meletios A Dimopoulos; A Moulopoulos; Kay Delasalle; Raymond Alexanian
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Hematology/oncology clinics of North America 1992;6(2):359-69.
1992: Meletios A Dimopoulos; J Goldstein; L Fuller; Kay Delasalle; Raymond Alexanian
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):587-90.
1991: Meletios A Dimopoulos; Bart Barlogie; Terry L Smith; Raymond Alexanian
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Annals of internal medicine 1991;115(12):931-5.
1991: M J Seider; Karen R Cleary; P van Tassel; Raymond Alexanian; Stimson P Schantz; A Frias; Lillian M Fuller
Plasma cell granuloma of the nasal cavity treated by radiation therapy.
Cancer 1991;67(4):929-32.
1990: Sundar Jagannath; Bart Barlogie; K Dicke; Raymond Alexanian; G Zagars; B Cheson; F C Lemaistre; L Smallwood; K Pruitt; D O Dixon
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Blood 1990;76(9):1860-6.
1990: Raymond Alexanian; Bart Barlogie
New treatment strategies for multiple myeloma.
American journal of hematology 1990;35(3):194-8.
1990: Bart Barlogie; Sundar Jagannath; D O Dixon; B Cheson; L Smallwood; A Hendrickson; J D Purvis; E Bonnem; Raymond Alexanian
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
Blood 1990;76(4):677-80.
1990: Hagop M Kantarjian; Raymond Alexanian; Charles Koller; Razelle Kurzrock; Michael J Keating
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: G J Ventura; Bart Barlogie; Jeane Hester; JC Yau; Charles F LeMaistre; R O Wallerstein; J A Spinolo; K A Dicke; L H Horwitz; Raymond Alexanian
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Bone marrow transplantation 1990;5(4):265-8.
1990: Raymond Alexanian; Bart Barlogie; S Tucker
VAD-based regimens as primary treatment for multiple myeloma.
American journal of hematology 1990;33(2):86-9.
1989: Bart Barlogie; W S Velasquez; Raymond Alexanian; Fernando Cabanillas
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(10):1514-7.
1989: Bart Barlogie; Joshua Epstein; P Selvanayagam; Raymond Alexanian
Plasma cell myeloma--new biological insights and advances in therapy.
Blood 1989;73(4):865-79.
1988: Bart Barlogie; Raymond Alexanian; L Smallwood; B Cheson; D Dixon; K Dicke; Fernando Cabanillas
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Blood 1988;72(6):2015-9.
1988: Joshua Epstein; Bart Barlogie; J Katzmann; Raymond Alexanian
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Blood 1988;71(4):861-5.
1988: P Selvanayagam; M Blick; F Narni; P van Tuinen; David Ledbetter; Raymond Alexanian; Grady F Saunders; Bart Barlogie
Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
Blood 1988;71(1):30-5.
1985: Bart Barlogie; Raymond Alexanian; D Dixon; L Smith; L Smallwood; K Delasalle
Prognostic implications of tumor cell DNA and RNA content in multiple myeloma.
Blood 1985;66(2):338-41.